Psychopharmacology Update: 2026

*A Zoom link to the program will be emailed to you the morning of the meeting. If you do not receive the link, email jhritz@mdpsych.org

Agenda:

7:00-7:15 Welcome

7:15-7:45 Rachel Talley, MD

7:45-8:15 Bernadette Wharton-Hawthorne, MD

8:15-8:45 Robert Hudak, MD

8:45-9:30 Question and Answer Session

Objectives:

• Understand the current evidence base for assisted outpatient treatment (AOT)
• Understand the state of Maryland’s implementation approach for AOT implementation, including the value of diverse stakeholder engagement
• Understand early successes and challenges of Maryland's AOT implementation

• Review the mechanism of action and current landscape of GLP-1s within the broader medical and psychiatric field
• Review current evidence for use of GLP-1s in eating disorders and discuss gaps in the literature
• Discuss assessing and mitigating risks for vulnerable populations who may be taking GLP-1s

• Define and discuss treatment resistant OCD
• Review the steps in medical management of treatment resistant patients
• Discuss the role of glutamatergic agents and the relevant research

Thank you to our Supporters:

Accreditation/Designation:

In support of improving patient care, this activity has been planned and implemented by American Psychiatric Association (APA) and the Maryland Psychiatric Society. APA is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The APA designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.